Phase I single-dose trial of XP 23829 in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 20 May 2014
At a glance
- Drugs XP 23829 (Primary)
- Indications Multiple sclerosis; Psoriasis
- Focus Adverse reactions; Pharmacokinetics
- 20 May 2014 Status changed from active, no longer recruiting to completed.
- 23 Mar 2013 Preliminary results presented at the 65th Annual Meeting of the American Academy of Neurology.
- 04 Oct 2012 Preliminary results have been reported in a XenoPort media release.